Table 1.
Characteristics of the discovery and replication cohorts
| PIAMA (Discovery) | EVA-PR (Replication) | COPSAC2010 (Replication) | MAKI (Replication) | |
|---|---|---|---|---|
| Sample size | 348 | 481 | 503 | 259 |
| Age (years) | 16.3 (0.20) | 15.5 (3.0) | 6.0 (0.2) | 5.8 (0.4) |
| Gender male | 179/348 (51.4%) | 248/481 (51.6%) | 217/503 (43.1%) | 146/259 (56.4%) |
| Smoking * | 37/297 (12.5%) | NA | 35/ 503 (6.9%) | 15/259 (5.8%) |
| Asthma | 23/348 (6.6%) | 236/481 (48.9%) | 31/503 (6.2%) | 20/255 (7.8%) |
| Rhinitis | 59/348 (17.0%) | 295/481 (61.3%) | 60/503 (53.3%) | 27/259(10.4%) |
| Eczema | 29/348 (8.3%) | 89/481 (18.5%) | 55/503 (10.8%) | 28/259 (10.8%) |
| Positive allergen-specific IgE | 162/348 (46.6%) | 311/481 (64.7%) | 85/503 (18.7%) | 56/ 205 (27.3%) |
| Allergy | 67/348 (19.3%) | 267/481 (55.5%) | 37/503 (8.9%) | 29/259 (11.2%) |
Continuous variables are presented as mean (SD); categorical variables are presented as (number of “yes”)/(total number (with this phenotype available)) (percentage).
PIAMA prevention and incidence of asthma and mite allergy birth cohort (Netherlands), EVA-PR epigenetic variation and childhood asthma in Puerto Ricans (USA), COPSAC2010 Copenhagen prospective study on asthma in childhood (Denmark), MAKI trial (the Netherlands).
*Smoking in COPSAC2010 and MAKI cohort refers to second-hand smoking.